Table 1

Clinical parameters of patients with PsA at baseline and 12 weeks following treatment

Anakinra n = 10

Etanercept n = 15

Week 0

Week 12

P-value

Week 0

Week 12

P-value


TJC28

9.5 (3 to 19)

7 (1 to 13)

0.033

11 (1 to 25)

2 (0 to 28)

0.004

TJC68

24.5 (9 to 52)

13.5 (3 to 35)

0.015

15 (3 to 57)

3 (0 to 38)

0.002

SJC28

8 (1 to 18)

5 (0 to 8)

0.032

4 (1 to 21)

1 (0 to 8)

0.005

SJC68

20.5 (6 to 27)

8 (0 to 23)

0.028

9 (3 to 43)

2 (0 to 16)

0.007

ESR

18.5 (3 to 79)

7.5 (2 to 46)

0.059

14 (4 to 91)

5 (1 to 26)

0.001

CRP

17 (4 to 70)

7.5 (0 to 29)

0.044

7 (0 to 42)

0 (0 to 18)

0.092

d VAS

66 (27 to 85)

47 (12 to 70)

0.051

44.5 (5 to 93)

15 (2 to 56)

0.002

p VAS

65.5 (21 to 91)

46.5 (20 to 75)

0.169

50 (22 to 93)

12 (2 to 66)

0.001

HAQ

1.25 (0.75 to 2.38)

1.13 (0.25 to 1.88)

0.057

1.13 (0 to 2.5)

0.25 (0 to 2.25)

0.01

DAS28

5.03 (3.77 to 7.16)

4.17 (2.35 to 5.98)

0.022

5.26 (3.08 to 6.95)

2.01 (0.14 to 5.35)

0.001


Median (range). d VAS, disease visual analogue scale; p VAS, pain visual analogue scale.

Pontifex et al. Arthritis Research & Therapy 2011 13:R7   doi:10.1186/ar3228

Open Data